FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations
The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
Contact Us: 4520 East West Highway, Suite 610 Bethesda, Maryland 20814 Phone: (301) 215-9099 Fax: (973) 215-9092 info@bcan.org © 2024 Bladder Cancer Advocacy Network. All…
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal…
Voting is now open! Voting closes August 31, 2023 at 11:59pm EST. Thank you to all who nominated a nurse colleague for the first-ever Cancer…
Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of…
A drop in our bone density as we age is inevitable, but not irreversible. In this article, we discuss why and how you should train…
The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.
This breakout session hosted at Transcatheter Interventions Online 2024 is for interventional cardiologists keen on advancing their expertise in vascular closure techniques, with a
Read our coverage of the major medical conferences that impact oncology
∗Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples “Federico II”, 80131 Naples, Italy. E-mail: E-mail Address: [email protected] Copyright © 2024, American…
The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.